Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer
Open Access
- 7 August 2008
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 58 (3) , 441-447
- https://doi.org/10.1007/s00262-008-0570-x
Abstract
Background The FOXP3 mRNA expression and the other regulatory T cell-related molecules were investigated and compared with clinicopathological parameters in human primary breast cancer. Method This study included 136 breast cancer patients operated in our department from 2003 to 2006. Total RNA was extracted from frozen normal breast and breast cancer tissues, and the expression of FOXP3, IL-10, TGFβ1 and CCL22 mRNA was evaluated using quantitative real-time RT-PCR. Result FOXP3, IL-10, TGFβ1 and CCL22 mRNA expressions were significantly higher in cancer tissue than in normal tissue, not only at pT1, 2, and 3 stages but also at the DCIS stage. There were positive correlations between FOXP3 and IL-10, FOXP3 and TGFβ1, as well as FOXP3 and CCL22 mRNA expressions, respectively. FOXP3 and IL-10 mRNA expressions were significantly upregulated in PgR-negative or HER2-positive tumors. Conclusion These results suggest that regulatory T cells are involved in tumor onset and progression in human primary breast cancer, possibly contributing to poor prognosis of patients with breast cancer.Keywords
This publication has 43 references indexed in Scilit:
- FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 OncogeneCell, 2007
- The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia‐inducible factor (HIF)‐2α but not HIF‐1αThe Prostate, 2007
- Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.Acta Oncologica, 2007
- Maturation of dendritic cells and T‐cell responses in sentinel lymph nodes from patients with breast carcinomaCancer, 2006
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJournal of Clinical Investigation, 2005
- Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood, 2005
- Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cellsThe Journal of Experimental Medicine, 2005
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 The Journal of Experimental Medicine, 2003
- Interleukin‐10 production by human carcinoma cell lines and its relationship to interleukin‐6 expressionInternational Journal of Cancer, 1993